Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

3.63 EUR

+1.11 %

5,591 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+1.11 %
-7.63 %
-0.68 %
-5.35 %
-22.10 %
-12.85 %
-8.68 %
-46.70 %
-20.74 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
77.88M EUR
Turnover
276.31K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Buy
Target price
Updated
17.12.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2.
2026

Annual report '25

6.5.
2026

Interim report Q1'26

8.5.
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Northwestern Medicine, with 11 hospitals and 200 locations in the Chicago area, is currently scaling AI-based retinopathy screening across its entire clinic network and its partner network. It’s hard to say if Aurora Aeye is involved, but it would seem like a rather heavy solution...
yesterday
by Sheikki
46
At least you’d imagine the relations are in order
yesterday
by carlos89
35
An interesting article caught my eye, stating that oculomics is moving from research to practice. Oculomics is no longer just a single AI use case but an evolving care model. AEYE Health is positioning itself from an algorithmic solution to clinical infrastructure, and Optomed is...
12/18/2025, 12:57 PM
by Mr. Stock
28
Apparently expanding quite nicely, and a major insurance player is setting the pace. That’s where those Christmas presents are developing under the surface linkedin.com National Account Manager | Retina Labs Looking for a new career challenge in 2026? Retina Labs has an exciting ...
4 hours ago
by Mr. Stock
22
CVS Health’s Investor Day material is interesting reading. They will be an AI-native company going forward; it would be strange if they weren’t also that in diabetic retinopathy screening. Volume and resulting efficiency gains would be available at Minute Clinics and especially in...
12/19/2025, 8:17 PM
by Sheikki
14
And how timely, Signify Health announced something like this (likely requires an FDA-approved portable?); signifyhealth.com Signify Health Adds Condition-Focused In-Home Visits Signify Health announced the launch of condition Focused Visits to provide screenings, preventive care ...
12/19/2025, 9:02 PM
by Mr. Stock
13
A small comment on this: if I recall correctly, the FDA returned Aurora AEYE’s permit application papers and demanded additional evidence, i.e., more image data. This is why the process with Aurora AEYE took years. With Lumo AEYE, I don’t believe in such a thing… experience teaches...
12/17/2025, 9:53 PM
by j.sälli
12
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.